AICAR
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
AICAR — short for 5-aminoimidazole-4-carboxamide ribonucleotide, and also known as acadesine or AICA riboside — is a small nucleotide analogue that has been studied for decades as a pharmacological tool for activating AMPK, the enzyme cells use to sense and respond to low energy. In the research literature it is frequently referred to as an exercise mimetic.
Interest in AICAR grew after preclinical work reported that it could reproduce some of the metabolic adaptations normally associated with physical training. Most of this evidence comes from cell and animal studies; robust human clinical data on performance or fat-loss outcomes is limited.
AICAR is not approved for human therapeutic use, and it is prohibited in sport at all times. It is sold only as a research chemical.
How it works
Once inside a cell, AICAR is converted to a compound (ZMP) that structurally resembles AMP, the molecule cells produce when energy runs low. By mimicking AMP, it can activate AMPK, which in turn shifts the cell toward energy-generating processes such as glucose uptake and fatty-acid oxidation while suppressing energy-consuming anabolic pathways.
Researchers have also noted that AICAR produces meaningful effects that appear to be independent of AMPK, so its full pharmacology is more complex than AMPK activation alone. The precise mechanisms and their relevance in humans are not well established.
Reported benefits
- Increased fat oxidation and glucose uptake in preclinical models
- Stimulation of mitochondrial biogenesis in skeletal muscle (animal data)
- Improved endurance capacity reported in sedentary rodents
- Studied as a reference AMPK activator across metabolic research
These are reported or studied effects from mostly preclinical work, not guaranteed outcomes in people.
Considerations & side effects
Because human safety data is scarce, the long-term risk profile of AICAR is not well characterized, and some sources note theoretical concerns tied to broad metabolic and cellular effects. Purity and identity also vary widely in the research-chemical market.
AICAR is banned in sport at all times, with no therapeutic use exemption available, so use by competitive athletes carries anti-doping consequences. It is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is AICAR?
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide, also called acadesine or AICA riboside) is a nucleotide analogue studied as an activator of AMPK, the cell's energy-sensing enzyme. It is often described in the research literature as an exercise mimetic.
Is AICAR FDA-approved?
No. AICAR is not approved by the FDA or any major regulator for human therapeutic use, and is sold for research purposes only.
Is AICAR banned in sport?
Yes. The World Anti-Doping Agency lists AICAR as a prohibited metabolic modulator, banned both in and out of competition, and no therapeutic use exemption is available for it.
Why is AICAR called an exercise mimetic?
In preclinical studies it activates several of the same metabolic pathways triggered by physical exercise, such as fat oxidation and mitochondrial biogenesis. This is a research characterization, not a proven substitute for exercise in humans.
References
Related compounds
Small molecule NNMT enzyme inhibitor. Increases NAD+ levels in fat cells, promoting energy expenditure and reducing fat accumulation without affecting appetite.
Lipotropic injection blend typically containing methionine, inositol, choline, and B12. Supports liver function and promotes fat metabolism.
Synthetic pan-estrogen-related receptor agonist functioning as an exercise mimetic. Activates metabolic pathways and increases mitochondrial density. Preclinical compound with limited human data.